MedTrace Logo

Gene Expression and DNA Variation Analysis of Sacs to Identify the Pathophysiology of Indirect Inguinal Hernia

NCT04634032 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-11-24

No results posted yet for this study

Summary

The aim of the project is to show that gene expression levels change in at least one of the GATA6 and T-box transcription factor 3 (TBX3) genes in indirect inguinal hernia sacs, thus revealing that this pathway causes an error in the sac closure pathway.

Indirect inguinal hernia is an important condition for human health as it is common in the community and can lead to life-threatening or permanent loss of function. In addition, since the treatment is performed surgically, the follow-up and treatment process of the patients should be managed carefully in terms of complications and costs. By explaining the mechanisms of the occurrence of this disease, important steps will be taken in terms of both human health and the development of science. Moreover, the data to be collected may open new horizons in the treatment of inguinal hernia.

20 inguinal hernia patients those consecutively applied to Trakya University Medical Faculty Department of Pediatric Surgery and 20 circumcision patients as control group will be included in the study.

Conditions

  • Indirect Inguinal Hernia
  • Genetic Predisposition to Disease

Interventions

GENETIC

mRNA expression and SNP analysis

mRNA expression and SNP analysis from samples

DIAGNOSTIC_TEST

Blood sampling

Peripheral blood sampling for SNP analysis

Sponsors & Collaborators

  • Trakya University

    lead OTHER

Principal Investigators

  • Oguz Kizilkaya · Trakya University

Eligibility

Max Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-22
Primary Completion
2020-11-01
Completion
2020-11-20

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04634032 on ClinicalTrials.gov